Concepedia

Sofiya Latifyan

SL

9

Publications

422

Citations

9

H-Index

2021

Active since

Affiliations

University of Lausanne(Current)

University Hospital of Lausanne

Sofiya Latifyan is an author at University of Lausanne specializing in tumor biology, immunology, and tumor immunity.

ORCID

Top concepts

Publications per year

2021–2024

9

Publications

9

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Eleonora Ghisoni, Alexandre Wicky, Hasna Bouchaab et al. · European Journal of Cancer · 2021 · 180 citations · Full text

<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

Sarah Boughdad, Sofiya Latifyan, Craig Fenwick et al. · Journal for ImmunoTherapy of Cancer · 2021 · 71 citations · Full text

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Julia Maria Ressler, Matthias Karasek, Lukas Koch et al. · Journal for ImmunoTherapy of Cancer · 2021 · 50 citations · Full text

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Johanna Chiffelle, David Barras, Rémy Pétremand et al. · Immunity · 2024 · 36 citations

, , +11

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Alexander Coukos, Julien Vionnet, Michel Obéid et al. · Journal for ImmunoTherapy of Cancer · 2022 · 33 citations · Full text

Rows per page

1–5 of 9